Distributed Bio announced an agreement with Boehringer Ingelheim to license the Distributed Bio SuperHuman Platform for accelerating biotherapeutics discovery across therapeutic areas.
“The SuperHuman Platform represents the culmination of a decade of our research in computational library design,” says Jacob Glanville, Co-Founder and Chief Science Officer of Distributed Bio. “From analyzing thousands of human immune systems with our machine learning AbGenesis platform, we have harvested from nature the rules of making exceptional therapeutic repertoires. The result is a library of 76 billion antibodies that contains over 5,000 hits against any antigen, including hundreds of picomolar binders, all thermostable, non-immunogenic, pre-screened by human blood and therapeutically developed in advance to avoid engineering delays downstream. This is an order of magnitude more molecules than can be generated by other technologies, and will enable our partners at Boehringer Ingelheim to search for ultra-high affinity, species-cross reactive and exquisitely specific therapeutic antibodies at unprecedented speeds.”
Under the terms of the agreement, Distributed Bio will transfer and license its proprietary SuperHuman 2.0 antibody discovery platform to Boehringer Ingelheim. Boehringer Ingelheim has also secured access to continued improvements to the SuperHuman Platform. Distributed Bio will receive an undisclosed annual licensing fee and future payments upon achievement of specified preclinical and clinical milestones.